Diario Oficial de la Unión Europea del 14/6/2023 - Comunicaciones e Informaciones
Text version What is this?Dateas is an independent website not affiliated with any government agency. The source of the PDF documents that we publish is the official agency stated in each of them. The text versions are non official transcripts that we do to provide better tools for accessing and searching information, but may contain errors or may not be complete.
Source: Diario Oficial de la Unión Europea - Comunicaciones e Informaciones
C 207/2
EN
Official Journal of the European Union
14.6.2023
V
Announcements
PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION
POLICY
EUROPEAN COMMISSION
Prior notification of a concentration Case M.11154 LUBEA / GEL / ESTEVE HEALTHCARE
Candidate case for simplified procedure Text with EEA relevance
2023/C 207/02
1. On 2 June 2023, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation EC No 139/2004 1.
This notification concerns the following undertakings:
LUBEA Cataman GmbH & Co. KG LUBEA, Germany, Grupo Esteve Life Sciences, S.L., GEL, Spain, Esteve Healthcare, S.L.U, Esteve Healthcare, Spain.
LUBEA and GEL will acquire within the meaning of Articles 31b and 34 of the Merger Regulation joint control of Esteve Healtchare.
The concentration is accomplished by way of purchase of shares.
2.
The business activities of the undertakings concerned are the following:
LUBEA is German company active in the acquisition, development, holding and sale of investments in companies as well as the establishment of companies. LUBEAs capital is held entirely by Lukas Asset Management SE & Co. KG.
GEL is a Spanish corporation headquartered in Barcelona. It is a family owned business owned by members of the Esteve family, with the sole purpose or holding 100 % of the shares in Esteve Healthcare.
Esteve Healthcare is a Spanish based international proprietary specialty pharmagroup, which is active in the entire pharmaceutical value chain, from preclinical research to manufacturing and the sale of finished dosage forms.
3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation EC No 139/2004 2 it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.
1 OJ L 24, 29.1.2004, p. 1 the Merger Regulation.
2 OJ C 366, 14.12.2013, p. 5.
